Chad vs Peru: HIV/AIDS deaths averted by antiretroviral therapy
Chad
5,621 deaths
in 2024
Peru
6,549 deaths
in 2024
Chad rank
33rd
Peru rank
30th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Chad
- Peru
How they compare
Peru currently reports 6,549 deaths against 5,621 deaths in Chad, a difference of 928 deaths.
That makes Peru's figure about 1.2 times Chad's.
The two have swapped places 6 times across 35 shared years of data; in 1990 it was Peru ahead.
Chad ranks 33rd and Peru ranks 30th of 157 countries.
Across the 4 decades both report, Chad averaged higher in 1 and Peru in 2.
Head to head by decade
| Decade | Chad | Peru | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 925.64 deaths | 908.88 deaths | 16.76 deaths | Chad |
| 2010s | 3,844 deaths | 4,028 deaths | 183.9 deaths | Peru |
| 2020s | 5,000 deaths | 6,039 deaths | 1,039 deaths | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Chad or Peru?
- Peru, at 6,549 deaths against 5,621 deaths in Chad as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Chad and Peru?
- 928 deaths, with Peru ahead.
- How many years of comparable data are there for Chad and Peru?
- 35 years are reported by both, from 1990 to 2024.
- How do Chad and Peru rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Chad ranks 33rd and Peru ranks 30th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.